Interestingly, yet another receptor of HMGB1, TIM‐3, expressed at the surface of tumour‐associated DCs, was recently shown to compete with nucleic acids for binding to HMGB1, thereby dampening the efficacy of antitumour DNA vaccines or chemotherapy.109. Here, HMGB1 is linked to neoplasm.